Skip to main content

FDA approves two additional strengths of generic schizophrenia drug


PITTSBURGH The Food and Drug Administration has approved two additional strengths of a generic version of a common schizophrenia drug.

Mylan announced Monday the approval of its haloperidol tablets in the 10 mg and 20 mg strengths. The company already markets the drug in strengths of 0.5 mg to 5 mg.

Haloperidol is used to control the symptoms of schizophrenia and Tourette syndrome and is a generic version of Johnson & Johnson’s Haldol, though J&J no longer manufactures Haldol in the tablet form. Haloperidol had sales of $21 million for the 12 months ending in March, according to IMS Health data.

This ad will auto-close in 10 seconds